These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 12097567)

  • 1. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
    Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
    J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
    Browning MJ; Huang AS; Reiss CS
    J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
    Wong SB; Siliciano RF
    J Virol; 2005 Feb; 79(3):1701-12. PubMed ID: 15650195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
    Haglund K; Forman J; Kräusslich HG; Rose JK
    Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
    J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
    Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
    J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J; Bojak A; Deml L; Wagner R
    Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
    Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
    J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.
    Kuate S; Stahl-Hennig C; Stoiber H; Nchinda G; Floto A; Franz M; Sauermann U; Bredl S; Deml L; Ignatius R; Norley S; Racz P; Tenner-Racz K; Steinman RM; Wagner R; Uberla K
    Virology; 2006 Jul; 351(1):133-44. PubMed ID: 16616946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.
    Yokomaku Y; Miura H; Tomiyama H; Kawana-Tachikawa A; Takiguchi M; Kojima A; Nagai Y; Iwamoto A; Matsuda Z; Ariyoshi K
    J Virol; 2004 Feb; 78(3):1324-32. PubMed ID: 14722287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.
    Qiu JT; Song R; Dettenhofer M; Tian C; August T; Felber BK; Pavlakis GN; Yu XF
    J Virol; 1999 Nov; 73(11):9145-52. PubMed ID: 10516021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
    Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
    J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    Rose NF; Roberts A; Buonocore L; Rose JK
    J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.
    Marques ET; Chikhlikar P; de Arruda LB; Leao IC; Lu Y; Wong J; Chen JS; Byrne B; August JT
    J Biol Chem; 2003 Sep; 278(39):37926-36. PubMed ID: 12824194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.